TP53 status may predict benefit from cetuximab in high-risk, locally advanced rectal cancer: Results of the EXPERT-C trial

Autoria(s): Sclafani, F.; Gonzalez, D.; Cunningham, D.; Wilson, S.H.; Peckitt, C.; Tabernero, J.; Glimelius, B.; Cervantes, A.; Brown, G.; Chau, I.
Data(s)

01/09/2013
Identificador

http://pure.qub.ac.uk/portal/en/publications/tp53-status-may-predict-benefit-from-cetuximab-in-highrisk-locally-advanced-rectal-cancer-results-of-the-expertc-trial(4453a346-e05c-4c1d-9eed-2c37d5d68e83).html
Idioma(s)

eng
Direitos

info:eu-repo/semantics/restrictedAccess
Fonte

Sclafani , F , Gonzalez , D , Cunningham , D , Wilson , S H , Peckitt , C , Tabernero , J , Glimelius , B , Cervantes , A , Brown , G & Chau , I 2013 , ' TP53 status may predict benefit from cetuximab in high-risk, locally advanced rectal cancer: Results of the EXPERT-C trial ' European Journal of Cancer , vol 49 , pp. S4-S4 .
Tipo

article
Acesso ao item digital